Dr. Dogan is the Chief Executive Officer and Co-Founder of Cardio Diagnostics, Inc. with over 10 years’ experience in bridging medicine, engineering and artificial intelligence towards building solutions to fulfill unmet clinical needs such as in cardiovascular disease prevention. Coming from a family with a two-generation history of heart disease and having spent extensive time interacting with those affected by heart disease, she understands the pain points and founded Cardio Diagnostics to help prevent others from experiencing its devastating impacts. Dr. Dogan is a pioneer in artificial intelligence/machine learning-driven integrated genetic- epigenetic approaches, which includes highly cited publications, and platform presentations at the American Heart Association and American Society of Human Genetics. She co-invented the patent-pending cardiac technologies of Cardio Diagnostics (issued by European Patent Office in March 2021). In 2017, Dr. Dogan founded Cardio Diagnostics to commercialize these technologies towards making heart disease prevention and early detection more accessible, personalized and precise. Under her leadership, the company was awarded the prestigious One To Watch award in 2020 by Nature and Merck, has bootstrapped its way to become a technology leader in cardiovascular diagnostics, launched its first product for the US market in January 2021, secured both dilutive and non-dilutive funding and key relationships with world renowned organizations such as Mayo Clinic and Intermountain Healthcare. Dr. Dogan holds a PhD degree in Biomedical Engineering and BSE/MS degrees in Chemical Engineering from University of Iowa. She was named FLIK Womxn Entrepreneur to Watch in 2021.